Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

ANNOUNCEMENT

PROPOSED 2025 INTERIM PROFIT DISTRIBUTION PLAN

Shanghai Pharmaceuticals Holding Co., Ltd. (the "**Company**") convened the 25th meeting of the eighth session of the board of directors (the "**Board**") on 30 October 2025, and approved the "Proposal on the 2025 Interim Profit Distribution". The Board hereby announces that the Company proposes to distribute profits for the first half of 2025 based on the total share capital as of the record date. Further announcement will be made by the Company regarding the record date. The profit distribution plan (the "**Profit Distribution Plan**") is as follows:

The Company's consolidated net profit attributable to shareholders of the listed company for the first half of 2025 amounted to RMB4,458,864,876.61 (unaudited). The Company proposes to distribute cash dividend of RMB1.20 (tax inclusive) for every ten shares to all shareholders, based on the total share capital of 3,708,361,809 shares as at 30 June 2025. The total proposed cash dividend will therefore amount to RMB445,003,417.08 (tax inclusive), representing 9.98% of the consolidated net profit attributable to shareholders of the listed company for the first half of 2025. There was no conversion of capital reserve into share capital of the Company for the six months ended 30 June 2025.

If the Company's total share capital changes between the date of this announcement and the record date for the distribution, the Company intends to maintain distribution amount per share unchanged based on the total share capital as of the record date and the total profit distribution amount will be adjusted accordingly.

The Profit Distribution Plan has been approved by the Board and will take effect upon approval by the shareholders of the Company at the Company's general meeting.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
YANG Qiuhua
Chairman

Shanghai, the PRC, 31 October 2025

As of the date of this announcement, the executive Directors of the Company are Mr. YANG Qiuhua, Mr. SHEN Bo, Mr. LI Yongzhong and Mr. DONG Ming; the non-executive Director is Mr. ZHANG Wenxue; and the independent non-executive Directors are Mr. GU Zhaoyang, Mr. Manson FOK, Mr. WANG Zhong and Ms. MAN Kwan.

* *For identification purpose only*